Session Information
AABB Audioconference Series 2012
Click here to go to the previous page
Drug Induced Immune Hemolytic Anemia
Track
:
Technical/Clinical
Program Code:
124703
Date:
Wednesday, May 9, 2012
Time:
2:00 PM to 3:30 PM
EST
DIRECTOR
:
Michele Anastasi, MS, MT(ASCP)SBB, Off Tour & Phlebotomy Supervisor, Hines VA Hospital PLMS (113)
MODERATOR
:
Michele Anastasi, MS, MT(ASCP)SBB, Off Tour & Phlebotomy Supervisor, Hines VA Hospital PLMS (113)
SPEAKER
(S):
George Garratty, PhD, FRCPath, Scientific Director, American Red Cross Blood Services
Pat Arndt, MS, MT(ASCP)SBB, Senior Research Associate, American Red Cross
Description
Drug-induced immune hemolytic anemia (DIIHA) should be considered whenever any hemolytic anemia is suspected. More than 100 drugs can cause a positive direct antiglobulin test (DAT) and, in some patients, this will be associated with significant hemolysis. This session will review the pathophysiology of DIIHA, laboratory investigations, and examples of case histories.
- Assess the serologic findings associated with DIIHA
- Describe the different mechanisms of drug-induced immune hemolytic anemia (DIIHA)
- Identify drugs commonly associated with immune hemolysis
- List laboratory tests useful for making the diagnosis of DIIHA
| CE Category | CE Value |
|---|---|
| California Clinical Laboratory Personnel | 1.5 |
| California Nurse | 1.8 |
| Florida Laboratory Personnel | 1.8 |
| General Attendee | 1.5 |
| Physician | 1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.
 | Copyright © 2014 by MultiView, Inc. All website graphics, text, design, software, and other works are the copyrighted works of MultiView, Inc. All audio, video, presentation materials, logos and text are the copyrighted works of their respective owners. All Rights Reserved. Any redistribution or reproduction of any materials herein is strictly prohibited. |  |